STOCK TITAN

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024

NEXGEL (NASDAQ: NXGL), a provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Winter Conference 2024.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

NEXGEL (NASDAQ: NXGL), a provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Winter Conference 2024.

Chief Executive Officer Adam Levy will deliver a presentation on Tuesday, December 10th at 10:30 a.m. ET. The two-day conference will take place on December 10-11, 2024. Interested parties can access the webcast presentation through the provided link, and one-on-one investor meetings can be arranged through iAccess representatives or KCSA Strategic Communications.

Loading...
Loading translation...
Argus Session date unavailable
-0.91% session move Open Argus
Details

News Market Reaction – NXGL

The recorded move for NXGL in the trading session of this news was -0.91%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

LANGHORNE, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 and 11, 2024.

iAccess Alpha Virtual Conference Details:
Date: December 10-11, 2024
Presentation Day and Time: Tuesday, December 10th at 10:30 a.m. ET
Webcast: https://www.webcaster4.com/Webcast/Page/3074/51540

To schedule a one-on-one investor meeting with Mr. Levy, please contact your representatives at iAccess or email KCSA Strategic Communications at NEXGEL@KCSA.Com.

About NEXGEL, Inc.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
NEXGEL@KCSA.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is NEXGEL (NXGL) presenting at the iAccess Alpha Winter Conference 2024?

NEXGEL will present on Tuesday, December 10th, 2024, at 10:30 a.m. ET during the iAccess Alpha Virtual Best Ideas Winter Conference.

How can investors schedule meetings with NEXGEL (NXGL) at the iAccess conference?

Investors can schedule one-on-one meetings with CEO Adam Levy by contacting iAccess representatives or emailing KCSA Strategic Communications at NEXGEL@KCSA.Com.

What products does NEXGEL (NXGL) specialize in?

NEXGEL specializes in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, offering both medical and over-the-counter (OTC) products.

Where can I watch NEXGEL's (NXGL) presentation at the iAccess conference?

The presentation can be accessed via webcast at https://www.webcaster4.com/Webcast/Page/3074/51540

Keep reading